Dublin, Ireland-headquartered protein specialist Prothena (Nasdaq: PRTA) announced that US pharma major Bristol Myers Squibb (NYSE: BMY) has obtained the exclusive global license for PRX019.
BMS will pay $80 million upfront to Prothena, which will also be eligible to receive development, regulatory, and sales milestone payments of up to $617.5 million. Additionally, Prothena will be eligible for tiered royalties on net sales.
The US Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target, in December 2023. Prothena plans to initiate the Phase I clinical trial for PRX019 by year-end 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze